You are here

Article Text

Article menu
Download PDFPDF
Short report
Tremor: a newly described adverse event with long-term itraconazole therapy
  1. Jodi M Lestner1,
  2. David W Denning1,2,3
  1. 1Department of Transitional Medicine, The University of Manchester, Manchester, UK
  2. 2Regional Mycology Laboratory, Manchester, UK
  3. 3Wythenshawe Hospital, Manchester, UK
  1. Correspondence to Miss Jodi M Lestner, The University of Manchester, Room 1.800, Stopford Building, Oxford Road, Manchester M13 9PT, UK; jodi.lestner{at}postgrad.manchester.ac.uk

Abstract

Itraconazole is a widely prescribed triazole antifungal drug, often given for long periods. The authors report five cases of tremor related to itraconazole therapy, which occurred within 1–12 months of initiating treatment and resolved gradually following itraconazole withdrawal.

  • Itraconazole
  • side effect
  • tremor
  • microbiology
  • neuropharmacology
  • neurotoxicology
  • pharmacology

https://doi.org/10.1136/jnnp.2009.174706

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding This study was funded by The Moulton Trust. The Fungal Research Trust supports the Regional Mycology Laboratory's culture collection.

    • Competing interests In the past 5 years, DWD has received grant support from Astellas, Merck, Pfizer, F2G, OrthoBiotech, Indevus, Basilea, the Fungal Research Trust, the Wellcome Trust, the Moulton Trust, The Medical Research Council, The National Institute for Health Research, The Chronic Granulomatous Disease Research Trust, the National Institute of Allergy and Infectious Diseases and the European Union. He has been an advisor/consultant to Basilea, Vicuron (now Pfizer), Pfizer, Schering Plough, Indevus, F2G, Nektar, Daiichi, Sigma Tau, Astellas, Gilead and York Pharma. He has been paid for talks on behalf of Schering, Astellas, Merck, GSK, Chiron, AstraZeneca and Pfizer. He holds founder shares in F2G Ltd and Myconostica Ltd, both University of Manchester spin-out companies.

    • Provenance and peer review Not commissioned; externally peer reviewed.